This is nothing new but I've had trouble remembering the title. This is a large (n= 586) phase 3 trial of Rux vs BAT where BAT is HU and IFN. I think some members are in it.
clinicaltrials.gov/study/NC...
This should provide the best comparison of the three therapies to date. They allow non-peg IFN, but I don't expect this is in use anywhere now. It's open label, reasonable since the drugs are observably very different.
that will be interesting as it’s not patients who were HU resistant this time
It has a specific exclusion of these pts, which is likely what you refer:
"OR resistance/intolerance to that (cytoreductive) therapy" This would include those resistant to any of the three. This should give a better result for all three arms, but maybe to different extents. I think this wide exclusion is unique.
In the IFN, they include Intron® A, Roferon® A. These are obsolete and not available, it's strange these are in there.
My doctor Professional Chang, based in Shanghai, China. He has taken Rux+IFN this therapeutic regimen for more than 12 years already! now he also has a lot of different medication combination for different MPN patient.👍
Approved or Trials of RBC lowering drugs?
Great results from Mylofibrosis clinical trial.
Trial or not to Trial
Future clinical trial with good evidence
Dual Vaccine Trial in Myeloproliferative Neoplasms
